On Monday, Novo Nordisk A/S (NYSE:NVO) announced headline results from the REDEFINE 2 phase 3 trial in the global REDEFINE program.
REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to placebo.
The trial included 1,206 randomized people with obesity or overweight, type 2 diabetes, and a mean baseline body weight of 102 kg.
The REDEFINE 2 trial was based on a flexible protocol, allowing patients to modify their dosing throughout the trial.
Also Read: Weight Loss Drugs Soar While Global Obesity Rates Climb, To Hit 50% Of Adults By 2050 Says New Report
After 68 weeks, 61.9% of patients treated with CagriSema were on the highest dose.
When evaluating treatment effects, if all people adhered to treatment, people treated with CagriSema achieved a weight loss of 15.7% after 68 weeks compared to 3.1% with placebo.
A co-primary endpoint was a weight loss of 5% or more after 68 weeks, which was achieved by 89.7% of patients on CagriSema, compared to 30.3% by placebo.
When applying the treatment policy estimand, people treated with CagriSema achieved a superior weight loss of 13.7% compared to 3.4% with placebo.
In the trial, CagriSema appeared to have a safe and well-tolerated profile. The most common adverse events with CagriSema were gastrointestinal, and the vast majority were mild to moderate and diminished over time, consistent with the GLP-1 receptor agonist class.
In December, in the REDEFINE 1 Phase 3 trial, CagriSema achieved a weight loss of 22.7% after 68 weeks compared to a reduction of 11.8% with cagrilintide 2.4 mg, 16.1% with semaglutide 2.4 mg and 2.3% with placebo alone, below the Street expectations of 25%.
Novo Nordisk expects to file for the first regulatory approval of CagriSema in the first quarter of 2026.
The detailed results from REDEFINE 1 and REDEFINE 2 will be presented at a scientific conference in 2025.
Price Action: At the last check on Tuesday, NVO stock was up 0.49% at $79.35 during the premarket session.
Read Next:
Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.
Get the latest stock analysis from Benzinga?
This article Novo Nordisk's Combo Drug CagriSema Shows 16% Weight Reduction In Second Phase 3 Trial originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。